GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Vir Biotechnology

GlaxoSmithKline plc (NYSE: GSK) said that its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology Inc (NASDAQ: VIR) is effective against all mutations of the new Omicron coronavirus variant, citing new data from preclinical studies. The data shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein.

Preclinical Data Shows GSK-Vir COVID-19 Drug Works Against All Omicron Mutations

A second batch of preclinical data shows sotrovimab is effective against all 37 mutations identified to date in the spike protein of Omicron.

Glaxo and Vir Antibody Drug Works on Omicron Mutations, New Data Show

A drug co-developed by GlaxoSmithKline PLC (LSE:GSK) to treat moderate-to-severe Coronavirus (COVID-19) cases is effective against the Omicron variant, according to a second batch of positive pre-clinical data. The latest results from a test of sotrovimab against a pseudo-virus tally with the earlier information released on December 2.

Covid drug co-developed by GlaxoSmithKline effective against Omicron variant, second preclinical study shows

GlaxoSmithKline PLC ( GSK , Financial) made another big move last week that may help get activist investor Elliott Advisors off its back. The British drug giant and the University of Oxford are starting a new center aimed at developing more effective treatments and at a faster rate, BioPharma Dive reported.

GlaxoSmithKline Makes Another Big Bet on Brain Drugs

Amgen

Bristol-Myers

These three pharmaceutical stocks could buffer your portfolio against further market turbulence.

3 Must-Own Dividend Stocks in This Chaotic Market

I tend to disregard most financial academics, with their efficient market hypothesis nonsense. That said, and because he's not in that crowd, I really enjoy following Robert Shiller's work.

Narrative Pharmaceuticals: Omicron vs. GlaxoSmithKline and Vir's Treatment

Longeveron

Merck

Health care stocks seem to be in vogue again as the Omicron Covid variant spreads globally.

Hot Stocks To Buy Right Now? 3 Health Care Stocks To Know

GSK vs. NVO: Which Stock Is the Better Value Option?

GSK vs. NVO: Which Stock Should Value Investors Buy Now?

Glaxo (GSK) and Vir Biotechnology announce promising pre-clinical data from the study of their antibody candidate, sotrovimab, against mutations found in the Omicron variant.

Glaxo (GSK), Vir COVID Drug Appears Effective Against Omicron

GlaxoSmithKline says early tests show that its antibody treatment was effective against the new strain, which was first identified in southern Africa.

Glaxo Antibody Drug Works Against Omicron, Tests Show

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced an update to bioRxiv, a preprint server, with preclinical data for sotrovimab, COVID-19 targeting monoclonal antibody. The data demonstrated that sotrovimab retains activity against key mutations of the new Omicron SARS-CoV-2 variant, including those found in the binding site of sotrovimab.

Vir Biotech - GSK's COVID-19 Antibody Shows Preclinical Activity Against Omicron Variant

Glaxo and Vir Say Early Tests Show Antibody Drug Works Against Omicron

A drug co-developed by GlaxoSmithKline PLC (LSE:GSK) to treat moderate-to-severe Covid cases is effective against the Omicron variant, according to preclinical data. GSK said it will confirm the read-out with further lab-based pseudo-virus work on its discovery, called sotrovimab, which was jointly developed with Nasdaq-listed Vir Biotechnology.

GlaxoSmithKline drug effective against Omicron variant

They're very similar companies on the surface, but one is planning for a big disruption.

Better Pharma Stock: GlaxoSmithKline vs. Bristol-Myers Squibb

Vir Biotechnology has a Covid-19 treatment that its CEO says will do well against new variants. Amid uncertainty, VIR stock is climbing.

VIR Stock Pops Amid Renewed Omicron Variant Concerns. Here's Why.

Glaxo (GSK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Glaxo (GSK) Upgraded to Strong Buy: Here's Why

GlaxoSmithKline has been one of the few bright spots in the volatile biopharmaceutical space this year.

1 High-Yield Dividend Stock Worth Buying Right Now

Johnson & Johnson

Robert Califf got the nod, but current acting commissioner Janet Woodcock would have made a fine choice too.

Who Would Be the Best FDA Commissioner for Biotech Investors?

Apple

American Express

Citigroup

Caterpillar

Celsius Holdings

Dow Inc

Enphase Energy

Gritstone Oncology Inc

Intel

Intrepid Potash

McDonald's

Microsoft

Pfizer

Procter & Gamble

Trillium Therapeutics

Travelers

Walmart

Two sample Breakout Stocks for Week 48 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the portfolio is up +70.5% YTD despite a record high 26 weeks out 47 weeks this year in negative conditions above the 40 MG level.

Week 48 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

GlaxoSmithKline is on track to deliver a much better performance in 2022 as investors see evidence of the potential in both arms of the business, according to Berenberg. Appreciation of the consumer healthcare business should improve as it moves towards demerger from the pharma side, while data from trials should show that the new pharma-led GSK can deliver on its targets.

GlaxoSmithKline's appeal to become much clearer in 2022 says broker

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) entered a drug development deal with GlaxoSmithKline Plc (NYSE: GSK), under which GSK will develop and market Arrowhead's potential treatment for patients with fatty liver disease NASH. Under the pact, Arrowhead would get an upfront payment of $120 million and is in line for an extra $30 million to start a Phase 2 trial and another $100 million if Phase 2 is successful and leads to a Phase 3.

GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead

Viatris

These stocks are unlikely to beat the market, but they're great for dividend income.

2 Cheap Pharma Stocks That Pay A Tidy Dividend

AstraZeneca

Eli Lilly

Of the top nine members of Big Pharma with high dividend yields, Eli Lilly and Co. ( LLY , Financial) brings up the rear at 1.32%. But that hardly tells the full story.

Look to Big Pharma for Healthy Dividends

Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.

Glaxo (GSK), Vir to Supply COVID Drug Sotrovimab to Government

GSK or NVO: Which Is the Better Value Stock Right Now?

News for GlaxoSmithKline Stock (GSK)